SH3BGRL3-like protein: A promising drug target and biomarker (G83442)

Target Name: SH3BGRL3

NCBI ID: G83442

SH3BGRL3

SH3BGRL3-like protein: A promising drug target and biomarker

SH3BGRL3-like protein (SH3BP) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SH3BP is a member of the SH3BP family, which includes several structurally similar proteins that are involved in various cellular processes, including protein-protein interactions, signaling pathways, and cellular signaling pathways.

The SH3BP family has been identified as a potential drug target due to its involvement in various cellular processes that are linked to the development and progression of diseases. For example, SH3BP has been shown to play a role in the regulation of cell growth, apoptosis, and angiogenesis, which are all processes that are implicated in the development of cancer. Additionally, SH3BP has been shown to be involved in the regulation of signaling pathways, including the TGF-β pathway, which is involved in the development and progression of many diseases, including cancer.

One of the key challenges in the development of SH3BP as a drug target is its complex structure and the difficulty in predicting its functions. However, recent studies have provided some insights into the functions of SH3BP and its potential drug target properties.

SH3BP has been shown to play a role in the regulation of protein-protein interactions (PPIs) in various cellular contexts. PPIs are the interactions between two or more proteins that are involved in the regulation of various cellular processes, including cell growth, apoptosis, and signaling pathways. SH3BP has been shown to be involved in the regulation of PPIs that are involved in the regulation of cell growth, apoptosis, and angiogenesis.

In addition, SH3BP has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. The TGF-β pathway is a complex signaling pathway that is involved in the development and progression of many diseases, including cancer. SH3BP has been shown to be involved in the regulation of TGF-β signaling by regulating the activity of the transcription factor SMAD.

Furthermore, SH3BP has been shown to play a role in the regulation of cellular apoptosis. Apoptosis is a natural process that is involved in the regulation of cellular life and death, and it is implicated in the development and progression of many diseases, including cancer. SH3BP has been shown to be involved in the regulation of apoptosis by regulating the activity of the protein Bcl-2.

In conclusion, SH3BP is a protein that has been identified as a potential drug target and biomarker for various diseases due to its involvement in various cellular processes that are linked to the development and progression of diseases. The functions of SH3BP are still being explored, and its potential as a drug target and biomarker continue to be evaluated. However, its potential as a drug target and biomarker is an exciting area of research that may lead to new treatments for various diseases.

Protein Name: SH3 Domain Binding Glutamate Rich Protein Like 3

Functions: Could act as a modulator of glutaredoxin biological activity (Probable). May play a role in cytoskeleton organization (PubMed:34380438)

The "SH3BGRL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3BGRL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets